Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives

Pharmaceutical Research

Volumn 16, Issue 2, 1999, Pages 176-185

  Derendorf, Hartmut ^a   Meibohm, Bernd ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Modeling; Pharmacodynamics; Pharmacokinetics; Pharmacology

Indexed keywords

3 (5 DIPROPYLAMINOMETHYL 1,2,4 OXADIAZOL 3 YL) 8 FLUORO 5,6 DIHYDRO 5 METHYL 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPIN 6 ONE; BENZODIAZEPINE; FLUTICASONE PROPIONATE; HYDROCORTISONE; PROTHROMBIN; PYRIDOSTIGMINE; UNCLASSIFIED DRUG; WARFARIN;

CONCENTRATION RESPONSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; PRIORITY JOURNAL; REVIEW; STEADY STATE;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOKINETICS; PHARMACOLOGY; TIME FACTORS;

EID: 0032974197     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011907920641     Document Type: Review

References (66)

1. 1. G. Levy. Kinetics of drug action: an overview. J. Allergy Clin. Immunol. 78:754-761 (1986).
2. 2. N. H. G. Holford and L. B. Sheiner. Kinetics of pharmacological response. Pharmacol. Ther. 16:143-166 (1982).
3. 3. G. Levy, M. Gibaldi, and W. J. Jusko. Multicompartment pharmacokinetic models and pharmacologic effects. J. Pharm. Sci. 58:422-424 (1969).
4. 4. G. Levy. Kinetics of drug action in man. Acta Pharmacol. Toxicol. Copenh. 29 Suppl. 3:203-210 (1971).
5. 5. M. Gibaldi, G. Levy, and H. Weintraub. Drug distribution and pharmacologic effects. Clin. Pharmacol. Ther. 12:734-742 (1971).
6. 6. J. G. Wagner. Kinetics of pharmacologic response: I. Proposed relationship between response and drug concentration in the intact animal and man. J. Theor. Biol. 20:173-201 (1968).
7. 7. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358-371 (1979).
8. 8. N. H. G. Holford and L. B. Sheiner. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit. Rev. Bioeng. 5:273-322 (1981).
9. 9. B. Oosterhuis and C. J. van Boxtel. Kinetics of drug effects in man. Ther. Drug Monit. 10:121-132 (1988).
10. 10. J. D. Unadkat, F. Bartha, and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin. Pharmacol. Ther. 40:86-93 (1986).
11. 11. E. Fuseau and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin. Pharmacol. Ther. 35:733-741 (1984).
12. 12. E. Chan, A. McLachlan, R. O'Reilly, and M. Rowland. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin. Pharmacol. Ther. 56:286-294 (1994).
13. 13. M. Thibonnier, N. H. G. Holford, R. A. Upton, C. D. Blume, and R. L. Williams. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. J. Pharmacokinet. Biopharm. 12:559-573 (1984).
14. 14. S. Rohatagi, U. Täuber, K. Richter, and H. Derendorf. Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone. J. Clin. Pharmacol. 36:311-314 (1996).
15. 15. B. Meibohm and H. Derendorf. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modeling. Int. J. Clin. Pharmacol. Ther. 35:401-413 (1997).
16. 16. H. Derendorf and G. Hochhaus, Handbook of Pharmacokinetic/ Pharmacodynamic Correlation, CRC Press, Boca Raton, 1995.
17. 17. M. O. Karlsson, V. Molnar, J. Bergh, A. Freijs, and R. Larsson. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin. Pharmacol. Ther. 63:11-25 (1998).
18. 18. D. E. Nix, J. H. Wilton, J. Hyatt, J. Thomas, L. C. Strenkoski-Nix, A. Forrest, and J. J. Schentag. Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Antimicrob. Agents Chemother. 41:1108-1114 (1997).
19. 19. J. W. Mandema and D. R. Stanski. Population pharmacodynamic model for ketorolac analgesia. Clin. Pharmacol. Ther. 60:619-635 (1996).
20. 20. C. A. Shanks, M. J. Avram, T. C. Krejcie, T. K. Henthorn, and W. B. Gentry. A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. J. Pharmacokinet. Biopharm. 21:309-321 (1993).
21. 21. J. W. Blue and W. A. Colburn. Efficacy measures: surrogates or clinical outcomes. J. Clin. Pharmacol. 36:767-770 (1996).
22. 22. J. W. Lee, J. D. Hulse, and W. A. Colburn. Surrogate biochemical markers: precise measurement for strategic drug and biologics development. J. Clin. Pharmacol. 35:464-470 (1995).
23. 23. B. G. Reigner, P. E. O. Williams, I. H. Patel, J. L. Steimer, C. C. Peck, and P. van Brummelen. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Clin. Pharmacokinet. 33:142-152 (1997).
24. 24. V. P. Shah, K. K. Midha, S. Dighe, I. J. McGilveray, J. P. Skelly, A. Yacobi, T. Layloff, et al. Analytical method validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 81:309-312 (1992).
25. 25. W. A. Colburn. Selecting and validating biologic markers for drug development. J. Clin. Pharmacol. 37:355-362 (1997).
26. 26. G. Levy. Mechanism-based pharmacodynamic modeling. Clin. Pharmacol. Ther. 56:356-358 (1994).
27. 27. W. A. Colburn. Pharmacokinetic/pharmacodynamic modeling: what it is! J. Pharmacokinet. Biopharm. 15:545-555 (1987).
28. 28. A. Racine-Poon, L. Botta, T. W. Chang, F. M. Davis, D. Gygax, R. S. Liou, P. Rohane, et al. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin. Pharmacol. Ther. 62:675-690 (1997).
29. 29. J. O. Auler, E. B. Espada, E. Crivelli, T. B. G. Quintavalle, A. Kurata, N. A. G. Stolf, A. M. Issy, et al. Diclofenac plasma protein binding: PK-PD modeling in cardiac patients submitted to cardiopulmonary bypass. Braz. J. Med. Biol. Res. 30:369-374 (1997).
30. 30. G. Hochhaus, E. W. Schmidt, K. L. Rominger, and H. Möllmann. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharm. Res. 9:291-297 (1992).
31. 31. W. G. Kramer, A. J. Kolibash, R. P. Lewis, M. S. Bathala, J. A. Visconti, and R. H. Reuning. Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man. J. Pharmacokinet. Biopharm. 7:47-61 (1979).
32. 32. G. Segre. Kinetics of interaction between drugs and biological systems. Farmaco. Sci. 23:907-918 (1968).
33. 33. W. A. Colburn. Simultaneous pharmacokinetic and pharmacodynamic modeling. J. Pharmacokinet. Biopharm. 9:367-388 (1981).
34. 34. J. Dingemanse, J. Häussler, W. Hering, H. Ihmsen, S. Albrecht, M. Zell, H. Schwilden, and J. Schüttler. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of RO 48-6791, a new short-acting benzodiazepine, in young and elderly subjects. Br. J. Anaesth. 79:567-574 (1997).
35. 35. D. E. Salazar, D. R. Much, P. S. Nichola, J. R. Seibold, D. Shindler, and P. H. Slugg. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J. Clin. Pharmacol. 37:799-809 (1997).
36. 36. R. Nagashima, R. A. O'Reilly, and G. Levy. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin. Pharmacol. Ther. 10:22-35 (1969).
37. 37. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparision of four basic models of indirect pharmacodynamic responses. J. Pharmocokinet. Biopharm. 21:457-478 (1993).
38. 38. A. Sharma and W. J. Jusko. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br. J. Clin. Pharmacol. 45:229-239 (1998).
39. 39. D. Verotta and L. B. Sheiner. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J Pharmacokinet. Biopharm. 23:1-4 (1995).
40. 40. L. B. Sheiner and D. Verotta. Further notes on physiologic indirect response models. Clin. Pharmacol. Ther. 58:238-240 (1995).
41. 41. M. Wakelkamp, G. Alvan, and G. Paintaud. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide. Br. J. Clin. Pharmacol. 45:63-70 (1998).
42. 42. S. Rohatagi, A. Bye, C. Falcoz, A. E. Mackie, B. Meibohm, H. Möllmann, and H. Derendorf. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J. Clin. Pharmacol. 36:938-941 (1996).
43. 43. W. J. Jusko and H. C. Ko. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:406-419 (1994).
44. 44. Z. X. Xu, Y. N. Sun, D. C. DuBois, R. R. Almon, and W. J. Jusko. Third-generation model for corticosteroid pharmacodynamics: Roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J. Pharmacokinet. Biopharm. 23:163-181 (1995).
45. 45. A. I. Nichols, F. D. Boudinot, and W. J. Jusko. Second generation model for prednisolone pharmacodynamics in the rat. J. Pharmacokinet. Biopharm. 17:209-227 (1989).
46. 46. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth, M. Krieg, S. Tunn, and C. Möllmann. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J. Clin. Pharmacol. 33:115-123 (1993).
47. 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. Eur. J. Clin. Pharmacol. 49:37-44 (1995).
48. 48. B. Meibohm, G. Hochhaus, and H. Derendorf. Time dependency of the pharmacologic response to glucocorticoids. Clin. Pharmacol. Ther. 61:155 (1997).
49. 49. M. J. Chow, J. J. Ambre, T. I. Ruo, A. J. Atkinson, D. J. Bowsher, and M. W. Fischman. Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin. Pharmacol. Ther. 38:318-324 (1985).
50. 50. J. J. Ambre. Acute tolerance to pressor effects of cocaine in humans. Ther. Drug Monit. 15:537-540 (1993).
51. 51. H. C. Porchet, N. L. Benowitz, and L. B. Sheiner. Pharmacodynamic model of tolerance: application to nicotine. J. Pharmacol. Exp. Ther. 244:231-236 (1988).
52. 52. J. A. Bauer and H. L. Fung. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm. Res. 11:816-823 (1994).
53. 53. M. Wakelkamp, G. Alvan, J. Gabrielsson, and G. Paintaud. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin. Pharmacol. Ther. 60:75-88 (1996).
54. 54. Y. Hashimoto and L. B. Sheiner. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. J. Pharmacokinet. Biopharm. 19:333-353 (1991).
55. 55. L. B. Sheiner and T. M. Ludden. Population pharmacokinetics/ dynamics. Ann. Rev. Pharmacol. Toxicol. 32:185-209 (1992).
56. 56. L. Yuh, S. Beal, M. Davidian, F. Harrison, A. Hester, K. Kowalski, E. Vonesh, and R. Wolfinger. Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. Biometrics 50:566-575 (1994).
57. 57. S. Vozeh, J. L. Steimer, M. Rowland, P. Morselli, F. Mentre, L. P. Balant, and L. Aarons. The use of population pharmacokinetis in drug development. Clin. Pharmacokinet. 30:81-93 (1996).
58. 58. C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Clin. Pharmacol. 34:111-119 (1994).
59. 59. P. D. Kroboth, V. D. Schmith, and R. B. Smith. Pharmacodynamic modeling: Application to new drug development. Clin. Pharmacokinet. 20:91-98 (1991).
60. 60. R. Lieberman and J. McMichael. Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development. Ther. Drug Monit. 18:423-427 (1996).
61. 61. D. D. Breimer and M. Danhof. Relevance of the application of pharmacokinetic-pharmacodynamic modeling concepts in drug development. Clin. Pharmacokinet. 32:259-267 (1997).
62. 62. F. Mentre, F. Pousset, E. Comets, B. Plaud, B. Diquet, G. Montalescot, A. Ankri, et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin. Pharmacol. Ther. 63:64-78 (1998).
63. 63. M. Hale, W. Gillespie, S. Gupta, B. Tuk, and N. H. G. Holford. Clinical trial simulation: Streamlining your drug development process. Appl. Clin. Trials 5:35-40 (1996).
64. 64. R. Gieschke, B. G. Reigner, and J. L. Steimer. Exploring clinical study design by computer simulation based on pharmacokinetic/ pharmacodynamic modeling. Int. J. Clin. Pharmacol. Ther. 35:469-474 (1997).
65. 65. N. H. G. Holford. The target concentration approach to clinical drug development. Clin. Pharmacokinet. 29:287-291 (1995).
66. 66. Z. X. Xu, A. Rakhit, I. H. Patel, and P. van Brummelen. PK/PD modeling approach to support clinical development of a long-acting interferon (RO 25-3036) for the treatment of chronic hepatitis C. Clin. Pharmacol. Ther. 63:162 (1998).